Tag: 上海夜网AY

Governor Wolf and Senator Gene Yaw Host a Roundtable to Address Pennsylvania’s Opioid Epidemic

first_img April 28, 2016 SHARE Email Facebook Twitter Press Release,  Substance Use Disorder Williamsport, PA – Today, Governor Tom Wolf and Senator Gene Yaw were joined by Rep. Jeff Wheeland, state and local officials, law enforcement and health care professionals at the Pennsylvania College of Technology to discuss local and statewide efforts to lead the nation in combating the opioid abuse and heroin use epidemic in Pennsylvania. In an effort to confront this epidemic collaboratively, Governor Wolf is conducting roundtables statewide to discuss the initiatives of his administration, the state legislature, county agencies, treatment centers, hospitals, medical schools, and to listen to local officials about the challenges they are facing.“Fighting Pennsylvania’s opioid and heroin epidemic is a top priority for my administration,” said Governor Wolf. “These roundtables are an opportunity to work collaboratively with the General Assembly and community leaders to ensure Pennsylvania leads the nation in the fight to combat the opioid abuse and heroin use crisis.”“We appreciate the opportunity to sit down with Governor Wolf today in order to increase public awareness of the heroin and opioid crisis facing our rural counties,” Sen. Yaw said.  “However, this is not just a rural issue. It’s a statewide issue.  Fortunately, we have a coalition in Lycoming County called Project Bald Eagle that is working to stem the tide of heroin and opioid abuse through education, prevention, treatment, enforcement and data monitoring.  Undoubtedly, it will take a statewide-wide effort to combat this issue and we thank the Governor for his involvement.”Governor Wolf was joined by Secretary Gary Tennis, Representative Jeff Wheeland, Lycoming County Commissioner Rick Mirabito, Williamsport Mayor Gabriel Campana, and a number of other state and local leaders and health care professionals, students, and professors. The governor lauded the efforts of these legislators and drew attention to the work of the Center for Rural PA, a bipartisan, bicameral legislative agency chaired by Senator Gene Yaw, who has been holding hearings with the Center on the opioid abuse and heroin use crisis since 2014.Beginning in 2014, the Center for Rural Pennsylvania convened a series of statewide public hearings to examine the increasing use of heroin and opioid abuse and addiction rates in rural Pennsylvania communities. The hearings were in response to questions posed by state legislators on the increasing number of arrests and overdose deaths attributed to heroin and opioid abuse within their respective legislative districts.The Wolf Administration hopes that these discussions are just the beginning of a larger conversation with both Republicans and Democrats in the House and Senate as well as local officials, law enforcement, emergency responders, and health care professionals.“I look forward to continue working collaboratively with the General Assembly and community leaders to ensure Pennsylvania leads the nation in the fight to combat the opioid abuse and heroin use epidemic,” said Governor Wolf. “The magnitude of the addiction and overdose death epidemic in Pennsylvania is shocking: at least seven Pennsylvanians die every day from a drug overdose. With nearly 2,500 overdose deaths in Pennsylvania in 2014 and estimates that the 2015 total will be higher, a collaborative effort on the federal, state, and local levels is crucial in combating this crisis.”Some of the administration’s initiatives in the fight against heroin include: signing a statewide standing order for naloxone, making it possible for all Pennsylvanians to access this life-saving drug; equipping the Pennsylvania State Police with naloxone so that those troopers who are first on the scene of an overdose can have another tool on-hand during these emergencies; partnering with Adapt Pharma to make Narcan available to public high schools across the state at no cost; developing the ABC-MAP prescription drug monitoring program to detect and prevent prescription fraud and abuse, which contribute to addiction; and appointing a director for the state’s Prescription Drug Monitoring Program (PDMP) Office, who will work to ensure that the PDMP meets its goal of assisting healthcare professionals in identifying patients that would benefit from treatment.In an effort to curtail drug addiction and curb the supply of excess drugs that can be used illicitly, the Department of Health is leading an effort to build upon the opioid prescribing guidelines already created, including specialty specific guidelines for emergency department providers, dentists, obstetricians and gynecologists, and pharmacists. These guidelines give healthcare providers direction for safe and effective pain relief practices, with greater emphasis on non-opioid therapies and greater caution to prevent addiction and diversion. In addition, the DOH recently joined dozens of healthcare organizations, medical experts, and consumer advocacy groups in signing petitions requesting changes to federal pain management requirements that are believed to foster dangerous prescribing practices.DOH is also working with the Department of Drug and Alcohol Programs to develop the “warm hand-off” process, whereby overdose survivors would be taken directly from the emergency department to a licensed drug treatment provider, as well as Pennsylvania’s Prescription Drug Take-Back Program. This program helps communities properly dispose of unused prescriptions at any of the 400+ police station locations across Pennsylvania. To date, approximately 40,000 pounds of prescription drugs have been taken back and destroyed.Governor Wolf’s decision to expand Medicaid eligibility in Pennsylvania under the Affordable Care Act has greatly increased access to treatment services for hundreds of thousands of Pennsylvanians.Finally, Governor Wolf’s proposed 2016-17 budget provides more than $34 million to treat more than 11,250 new individuals with substance use disorder. The Department of Human Services will provide 25 new Opioid Use Disorder Centers of Excellence for individuals with substance use disorder, providing medication-assisted treatment and appropriate wraparound services, such as cognitive-based therapies. After this first phase of implementation, there will be a push for 25 more facilities that would have the capacity to treat 22,500 individuals total.# # #Like Governor Tom Wolf on Facebook: Facebook.com/GovernorWolfcenter_img Governor Wolf and Senator Gene Yaw Host a Roundtable to Address Pennsylvania’s Opioid Epidemiclast_img read more

Read More

Egypt’s Tourism Sector taps into Chinese Market

first_imgEgypt is working hard to attract Chinese tourists. Several conferences and events were organised to facilitate the procedures to send Chinese to Egypt. CCTV’s Yasser Hakim highlights Egypt’s efforts to increase its share of the chinese marketlast_img

Read More

Snails might be the key to making artificial robot brains

first_imgSnails are not exactly what you would call intelligent, but their brains might prove a good model for designing artificial robot brains. A new study from researchers at the University of Sussex shows how just two neurons in a snail’s brain can drive complex behavioral decisions. Specifically, researchers watched freshwater snails “decide” whether or not to have a snack.Decision-making neurophysiology, especially in more complex animals, is still poorly understood. So, starting with a relatively simple snail brain seems like a good first step. The outcome of this decision-making process is elementary, but the process might not be. The snail has to integrate information from its environment, figure out how it feels about that, and act based on its state. This is, after all, the sort of thing you want a robot to be able to do.The researchers used electrodes to measure electrical activity in the snail’s brain while it was searching for food. They discovered that the snail used controller and motivator neurons to determine whether or not it would eat. The first cell relayed information about the discovery (or not) of food. Meanwhile, the second cell told the first if the animal was actually hungry. You need both of these to eat at the right time. If there was no food present, the circuit would shut down to save energy.This might mean that the sort of decisions that can lead to complex tasks are actually very easy to design. Thus, a robot doesn’t necessarily need a server closet full of CPU cores cranking away on gigabytes of data to make decisions. This could make our future robot overlords much more efficient when they decide which humans to eliminate and which to enslave. Everyone wins.last_img read more

Read More

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal

first_imgReviewed by Alina Shrourou, B.Sc. (Editor)Sep 19 2018Exelixis, Inc. today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received approval from Health Canada of CABOMETYX® (cabozantinib) tablets for the treatment of adults with advanced renal cell carcinoma (RCC) who have received prior vascular endothelial growth factor (VEGF) targeted therapy. Health Canada granted CABOMETYX priority review status, which provided an accelerated review of Ipsen’s new drug submission.Related StoriesMathematical model helps quantify metastatic cell behaviorRetina can restructure itself following gene therapyAbcam Acquire Off-The-Shelf Diploid Library of Over 2,800 Knockout Cell Lines”The approval of CABOMETYX in Canada helps address a significant unmet need for patients with advanced kidney cancer whose disease has progressed on first-line therapy and who have limited treatments available,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer of Exelixis. “We are glad to be partnering with Ipsen to bring this much needed treatment option to these patients and look forward to our continued collaboration.”The Health Canada approval was based on results of the phase 3 pivotal METEOR trial in which CABOMETYX provided a statistically significant and clinically meaningful improvement in overall survival, progression-free survival and objective response rate as compared with everolimus in patients with advanced RCC who have received prior anti-angiogenic therapy.Under the terms of the Collaboration Agreement with Ipsen, Exelixis will receive a milestone payment of $5 million for the Health Canada approval. The payment will be made by Ipsen within the next 70 days. Source:http://ir.exelixis.com/phoenix.zhtml?c=120923&p=RssLanding&cat=news&id=2368033last_img read more

Read More